Next Article in Journal
Synthesis and Biodegradation of Poly(l-lactide-co-β-propiolactone)
Next Article in Special Issue
Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin
Previous Article in Journal
Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
Previous Article in Special Issue
Zampanolide, a Microtubule-Stabilizing Agent, Is Active in Resistant Cancer Cells and Inhibits Cell Migration
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(6), 1267; doi:10.3390/ijms18061267

Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity

1
Key Laboratory of Developmental Genes and Human Disease, Institute of Life Sciences, Southeast University, Nanjing 210096, China
2
School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China
3
State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China
4
Shandong Provincial Key Laboratory of Animal Resistance Biology, Institute of Biomedical Sciences, College of Life Sciences, Shandong Normal University, Jinan 250014, China
*
Authors to whom correspondence should be addressed.
Academic Editors: John H. Miller and Susan L. Mooberry
Received: 30 March 2017 / Revised: 9 June 2017 / Accepted: 11 June 2017 / Published: 20 June 2017
(This article belongs to the Special Issue Microtubule-Targeting Agents)
View Full-Text   |   Download PDF [1384 KB, uploaded 20 June 2017]   |  

Abstract

Centrosome aberrations have been implicated in the development and progression of breast cancer. Our previous worked show that centrosomal protein 70 (Cep70) regulates breast cancer growth and metastasis. However, it remains elusive whether Cep70 is implicated in the sensitivity of the anti-microtubule drug paclitaxel in breast cancer. Here we provide evidence that Cep70 is a mediator of paclitaxel sensitivity in breast cancer. Cell proliferation assays show that Cep70 expression correlates with paclitaxel sensitivity in breast cancer cell lines. In addition, paclitaxel sensitivity varies when altering Cep70 expression level. Mechanistic studies reveal that Cep70 interacts with tubulin, and promotes the ability of paclitaxel to stimulate microtubule assembly. These data demonstrate that Cep70 mediates paclitaxel sensitivity in breast cancer. View Full-Text
Keywords: Cep70; microtubule; paclitaxel sensitivity; breast cancer Cep70; microtubule; paclitaxel sensitivity; breast cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Shi, X.; Wang, Y.; Sun, X.; Wang, C.; Jiang, P.; Zhang, Y.; Huang, Q.; Liu, X.; Li, D.; Zhou, J.; Liu, M. Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity. Int. J. Mol. Sci. 2017, 18, 1267.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top